AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)

-- LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapy -- RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2023 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly

Related Keywords

United States ,Research Triangle Park ,North Carolina ,United Kingdom ,Edinburgh ,City Of ,Scotland ,Dennis Riedl ,Sheila Mikhail ,Bayer Ag ,National Center ,Linkedin ,National Institutes Of Health ,European Commission ,Drug Administration ,National Institutes Of Health Medline ,Rare Diseases Information Center ,Translational Sciences ,Trademark Office ,Committee For Orphan Medicinal Products ,European Medicines Agency ,Prnewswire Asklepios Biopharmaceutical Inc ,Asklepios Biopharmaceutical Inc ,Rare Form ,Muscular Dystrophy ,Orphan Medicinal Products ,Limb Girdle Muscular Dystrophy ,Limb Girdle Muscular Dystrophy Type ,Girdle Muscular Dystrophy Type ,National Institutes ,Health Medline Plus ,United States Food ,United States Patent ,Accessed February ,Advancing Translational Sciences ,Rare Diseases Information ,Askbio ,Eceives ,European ,Commission ,Orphan ,Drug ,Resignation ,Through ,Ased ,Ubsidiary ,Rainvectis ,003 ,Novel ,Investigational ,Gene ,Therapy ,Treatment ,Limb ,Girdle ,Muscular ,Dystrophy , ,